Browse the evidence

Maintaining a body weight loss of ≥7% of baseline (high Time in Target Range, TTR) is independently associated with a significantly lower risk of major adverse cardiovascular events in adults with overweight/obesity and type 2 diabetes, independent of mean body weight and weight variability.

For adults with type 2 diabetes and obesity, the key to reducing cardiovascular risk is not just losing weight, but keeping it off. Aim to maintain a 7% weight loss from your starting weight. Track your 'Time in Target Range' (TTR)—the percentage of time you stay within this 7% loss zone. Higher TTR is strongly linked to lower heart disease risk, independent of your average weight or how much it fluctuates. Focus on consistency and maintenance over the long term (years, not weeks).

Modest weight loss of 5–10% significantly improves cardiovascular and metabolic risk factors, whereas weight loss of ≥10% is required to reduce major cardiovascular events.

Focus on achieving a 5-10% weight reduction as a primary clinical goal for improving metabolic health markers like blood pressure and lipids. If the patient has established cardiovascular disease, aim for at least 10% weight loss to significantly lower the risk of major cardiovascular events. This can be achieved through lifestyle modifications, and if insufficient, anti-obesity medications or bariatric surgery should be considered.

GLP-1 analogues (e.g., semaglutide) and dual agonists (e.g., tirzepatide) produce robust weight loss (15-21%) that approaches or exceeds bariatric surgery efficacy, with potential independent cardiovascular benefits beyond weight loss.

For patients with obesity who have not achieved sufficient weight loss with lifestyle changes alone, consider GLP-1 analogues like semaglutide (2.4 mg weekly) or dual agonists like tirzepatide. These medications can produce 15-21% weight loss, approaching the efficacy of bariatric surgery, and may offer independent cardiovascular benefits.

Heavy-load resistance training preserves lean body mass in prostate cancer patients undergoing androgen deprivation therapy (ADT), effectively counteracting the muscle loss typically caused by the therapy, while simultaneously increasing muscle strength to a degree comparable to healthy elderly men.

If you are undergoing hormone therapy for prostate cancer, do not skip resistance training. Heavy lifting (using weights that feel hard for 6-12 reps, 2-3 times a week) will help you keep the muscle you have and make you stronger. You might not see your muscles get bigger like a healthy person would, but you will stop them from shrinking, which is a major win for your health and survival.

An online multidisciplinary collaborative weight loss management program significantly improves glycemic control (HbA1c, fasting, and postprandial blood glucose) and self-management abilities in obese or overweight patients with type 2 diabetes compared to conventional outpatient management.

If you have type 2 diabetes and are overweight, an online program with a dedicated team (doctor, dietitian, exercise coach, psychologist) can help you manage your blood sugar and weight better than standard clinic visits. You will need to use a smartphone app to log your food, exercise, and body measurements daily, and participate in online courses. The program provides regular feedback and support from experts to help you stay on track. This approach has been shown to significantly lower HbA1c and improve your ability to manage your health.

Personalized nutrition interventions yield significantly greater reductions in body weight, BMI, waist circumference, and LDL cholesterol in individuals carrying the FTO risk genotype (TT/TC) compared to those with the non-risk genotype (CC).

If you carry the FTO risk genotype (TT or TC), a personalized nutrition plan is likely to be significantly more effective for weight and lipid management than a standard one-size-fits-all approach. You should prioritize interventions that are tailored to your specific metabolic profile, as your body appears to respond more robustly to dietary changes in this genetic context.

Individualized Repetitions-in-Reserve (RIR) to velocity relationships provide acceptable prediction accuracy (mean error <2 repetitions) for resistance training monitoring and prescription, whereas general population models do not.

Stop using generic velocity charts for everyone. To prescribe training accurately, you must establish your own personal relationship between how fast the bar moves and how many reps you have left in reserve. Test this by performing sets to failure at different loads (e.g., 70%, 80%, 90% of 1RM) and recording the velocity for each Repetition-in-Reserve (RIR) level. Use this personal data to guide your daily training, adjusting loads to hit your specific velocity targets for desired RIRs, rather than guessing based on population averages.

Tirzepatide 15 mg once weekly is preferred for individuals with obesity and heart failure with preserved ejection fraction (HFpEF) to improve symptoms and functional capacity, irrespective of glycemic status or weight loss magnitude.

If you have obesity and heart failure with preserved ejection fraction (HFpEF), tirzepatide 15 mg once weekly is a preferred treatment to significantly reduce hospitalizations and improve your ability to walk and feel better, even if your blood sugar is normal or you don't lose a lot of weight.

Multireceptor incretin agonists (targeting GLP-1, GIP, and/or Glucagon receptors) produce clinically meaningful weight loss by simultaneously suppressing appetite via central nervous system pathways and increasing energy expenditure via peripheral metabolic activation.

If you have obesity, relying on willpower and diet alone often fails because your body fights back by slowing your metabolism and increasing hunger. Modern incretin-based medications work by targeting specific hormone receptors to simultaneously turn off the drive to eat and turn up your energy expenditure. This dual approach addresses the physiological root of obesity, offering significantly higher weight loss potential than lifestyle changes alone, with newer formulations designed to minimize side effects like nausea.

High protein intake is the most satiating macronutrient per calorie and promotes weight loss and fat loss when combined with calorie restriction, primarily by preserving lean mass and increasing energy expenditure.

Eating more protein helps you feel full and lose weight, especially if you are also eating fewer calories or exercising. It helps keep your muscles while you lose fat. However, just eating protein without exercise won't necessarily make you a better athlete or significantly stronger.

Combining high-intensity resistance training with chronic chicken meat intake significantly increases muscle strength and lean body mass in elderly women more effectively than either intervention alone.

For elderly women looking to build muscle and strength, combining resistance training (3 times a week) with regular chicken meat consumption (approx. 110g, 3 times a week) is more effective than doing either one alone. Ensure the training intensity is challenging (around 70% of your max lift) and adjust weights as you get stronger.

BCAA supplementation (500mg Leucine/250mg Isoleucine/250mg Valine daily) significantly reduces Delayed Onset Muscle Soreness (DOMS) and perceived fatigue in women undergoing resistance training, with effects exceeding those in men.

If you are a female recreational weightlifter, taking a BCAA supplement containing 2.5g Leucine, 1.25g Isoleucine, and 1.25g Valine daily may significantly reduce your muscle soreness and perceived fatigue after workouts compared to not taking them. This allows for better recovery between sessions. Men in this study saw greater strength gains but less specific recovery benefit from BCAAs compared to women.

First-line GLP-1 RA initiation is associated with greater HbA1c reduction compared to metformin in both patients with prediabetes and diabetes.

GLP-1 RA is more effective than metformin at lowering HbA1c levels in both prediabetes and diabetes. This makes it a potent option for achieving glycemic targets, though adherence should be monitored.

Tirzepatide produces significantly greater weight loss than semaglutide in patients with type 2 diabetes, with a mean difference of -4.84 kg favoring tirzepatide.

If you have Type 2 Diabetes and are choosing between Tirzepatide and Semaglutide for weight loss, Tirzepatide is likely to produce greater weight loss (approx. 4.8 kg more on average). Both drugs share similar gastrointestinal side effect profiles, which are generally manageable. The choice may depend on individual response, tolerability, and cost/insurance coverage, but Tirzepatide shows superior efficacy in head-to-head comparisons.

Combining high adherence to a macronutrient-restricted diet (low-carb or low-fat) with high dietary quality yields significantly greater weight loss than either factor alone or low adherence/quality.

If you are following a low-carb or low-fat diet, your weight loss success depends heavily on two things: how closely you stick to the diet (adherence) and how nutritious the food is (quality). Simply cutting carbs or fat without focusing on whole foods and dietary quality may not lead to significant weight loss. To maximize results, aim for both high adherence to your chosen macronutrient limits and high dietary quality (e.g., high Healthy Eating Index score).

Sugar-sweetened beverage (SSB) consumption is a major global driver of incident Type 2 Diabetes and Cardiovascular Disease, with the highest proportional burdens found in Latin America/Caribbean and Sub-Saharan Africa.

Reduce or eliminate sugar-sweetened beverages to significantly lower your risk of Type 2 Diabetes and heart disease. This is especially critical if you live in or originate from regions with high SSB consumption like Latin America or Sub-Saharan Africa, where the population-level risk is highest.

GLP-1 and GIP receptor agonists (semaglutides and tirzepatides) effectively reverse overweight, obesity, and type 2 diabetes by targeting neuro-hormonal pathways, achieving mean weight reductions of 10.2% and 15.0% respectively, whereas lifestyle interventions fail to produce permanent weight loss due to compensatory biological mechanisms.

If you have struggled to maintain weight loss through diet and exercise alone, recognize that this is likely due to biological resistance (hormonal signals), not a lack of willpower. Consult a healthcare provider about GLP-1/GIP agonists (like semaglutide or tirzepatide), which target these specific pathways. While currently expensive, these treatments offer a clinically proven path to significant weight loss and diabetes management that lifestyle changes alone have failed to provide for most people.

GLP-1 receptor agonists (Liraglutide, Semaglutide) and dual GIP/GLP-1 agonists (Tirzepatide) offer superior weight loss compared to older anti-obesity medications.

Newer injectable medications like Semaglutide and Tirzepatide provide significantly greater weight loss than older drugs. They are taken weekly and are highly effective, but access and cost can be barriers.

Multicomponent group-based physical activity interventions (combining aerobic, resistance, and/or mind-body exercises) significantly improve mobility, physical function, balance, and muscle strength in community-dwelling older adults.

To stay mobile as you age, join a group exercise class that mixes walking, strength training, and balance exercises. This combination is proven to keep your muscles strong and your balance sharp, reducing your risk of falls. You don't need supplements to achieve this; consistent group activity is the key.

Aerobic and resistance training interventions significantly reduce the risk of falls in older adults.

If you are worried about falling, start a group exercise program that includes strength and balance work. This is the most effective way to lower your fall risk. Staying inactive due to fear actually makes you more vulnerable.

Resistance training is the most effective exercise intervention for improving muscle strength, physical performance, and mitigating muscle mass loss in older adults with sarcopenia.

For older adults concerned about muscle loss, resistance training is the most proven exercise method to maintain strength and independence. It should be considered a first-line treatment, ideally prescribed personally to fit individual needs.

Next-generation multi-receptor agonists (e.g., Tirzepatide, a dual GLP-1/GIP agonist) offer superior weight loss and metabolic efficacy compared to single GLP-1RAs.

If single GLP-1 medications (like Ozempic or Wegovy) aren't providing enough weight loss or metabolic improvement, ask your doctor about dual-agonists like Tirzepatide. These newer drugs target two hormones (GLP-1 and GIP) and have shown even greater weight loss in clinical trials. They are approved for both diabetes and obesity management.

Daily protein supplementation (12g additional protein via skimmed milk/soy isolate) combined with simple calisthenic and aerobic exercise for 8 weeks significantly increases lean mass and appendicular muscle mass in healthy sedentary adults.

If you are sedentary and want to build muscle, you don't need a gym membership or expensive gear. Add 12g of protein daily (e.g., via a supplement or food) and perform simple bodyweight exercises (like squats and push-ups) 3 times a week, plus walk 150 minutes a week. Doing this for 8 weeks will likely increase your lean muscle mass.

Lengthened partial repetitions (LPs) elicit similar muscle hypertrophy and strength-endurance adaptations as full range of motion (ROM) repetitions in resistance-trained individuals.

If you are a trained lifter, you don't need to force full range of motion if it causes pain or joint issues. You can use lengthened partial reps (starting from the stretched position and going halfway up) and still build muscle and strength just as well as doing full reps. Just make sure you are training to failure and emphasizing the stretch.